Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · IEX Real-Time Price · USD
2.550
-0.100 (-3.77%)
At close: Apr 25, 2024, 4:00 PM
2.580
+0.030 (1.18%)
After-hours: Apr 25, 2024, 4:49 PM EDT
Heron Therapeutics Market Cap
Heron Therapeutics has a market cap or net worth of $383.34 million as of April 25, 2024. Its market cap has increased by 19.94% in one year.
Market Cap
383.34M
Enterprise Value
482.56M
1-Year Change
19.94%
Ranking
Category
Stock Price
$2.55
Market Cap Chart
Since December 1, 1998, Heron Therapeutics's market cap has increased from $127.40M to $383.34M, an increase of 200.89%. That is a compound annual growth rate of 4.43%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 24, 2024 | 398.40M | -5.35% |
Apr 23, 2024 | 420.90M | 8.09% |
Apr 22, 2024 | 389.40M | -1.89% |
Apr 19, 2024 | 396.90M | -2.58% |
Apr 18, 2024 | 407.40M | -2.16% |
Apr 17, 2024 | 416.40M | -5.47% |
Apr 16, 2024 | 440.50M | -0.68% |
Apr 15, 2024 | 443.50M | 1.37% |
Apr 12, 2024 | 437.50M | -1.02% |
Apr 11, 2024 | 442.00M | 7.70% |
Apr 10, 2024 | 410.40M | -2.49% |
Apr 9, 2024 | 420.90M | 1.81% |
Apr 8, 2024 | 413.40M | - |
Apr 5, 2024 | 413.40M | 7.02% |
Apr 4, 2024 | 386.30M | - |
Apr 3, 2024 | 386.30M | 0.78% |
Apr 2, 2024 | 383.30M | -5.92% |
Apr 1, 2024 | 407.40M | -2.16% |
Mar 28, 2024 | 416.40M | 1.09% |
Mar 27, 2024 | 411.90M | - |
Mar 26, 2024 | 411.90M | -7.13% |
Mar 25, 2024 | 443.50M | -0.67% |
Mar 22, 2024 | 446.50M | -2.62% |
Mar 21, 2024 | 458.50M | - |
Mar 20, 2024 | 458.50M | 3.38% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Humacyte | 474.85M |
Taysha Gene Therapies | 474.09M |
Nevro | 465.71M |
Acelyrin | 464.31M |
Editas Medicine | 463.80M |
Fulcrum Therapeutics | 462.04M |
Theravance Biopharma | 458.05M |
IGM Biosciences | 455.66M |